Contact – +1-276-477-5910
 Email – [email protected]

Home >>

Chemicals & Materials

>>

Irritable Bowel Syndrome Treatment Market


Irritable Bowel Syndrome Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Report code: SDMRCH1554681 | Industry: Chemicals & Materials | Published On: 1/16/2020


Summary

Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.

The global Irritable Bowel Syndrome Treatment market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Irritable Bowel Syndrome Treatment market segmented into
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others

Based on the end-use, the global Irritable Bowel Syndrome Treatment market classified into
Hospital
Clinic
Home Care

Based on geography, the global Irritable Bowel Syndrome Treatment market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are
Abbott Laboratories
Synergy Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Ardelyx, Inc.
Astellas Pharma Inc.
Novartis AG
GlaxoSmithKline plc.
Ironwood Pharmaceuticals, Inc.

Table  of  Contents
1    RESEARCH  SCOPE
        1.1  Research  Product  Definition
        1.2  Research  Segmentation
                1.2.1  Product  Type
                1.2.2  Main  product  Type  of  Major  Players
        1.3  Demand  Overview
        1.4  Research  Methodology
2  GLOBAL  IRRITABLE  BOWEL  SYNDROME  TREATMENT  INDUSTRY
        2.1  Summary  about  Irritable  Bowel  Syndrome  Treatment  Industry
        2.2  Irritable  Bowel  Syndrome  Treatment  Market  Trends
                2.2.1  Irritable  Bowel  Syndrome  Treatment  Production  &  Consumption  Trends
                2.2.2  Irritable  Bowel  Syndrome  Treatment  Demand  Structure  Trends
        2.3  Irritable  Bowel  Syndrome  Treatment  Cost  &  Price
3    MARKET  DYNAMICS
        3.1  Manufacturing  &  Purchasing  Behavior  in  2020
        3.2  Market  Development  under  the  Impact  of  COVID-19
                3.2.1  Drivers
                3.2.2  Restraints
                3.2.3  Opportunity
                3.2.4  Risk
4    GLOBAL  MARKET  SEGMENTATION
        4.1  Region  Segmentation  (2017  to  2021f)
                4.1.1  North  America  (U.S.,  Canada  and  Mexico)
                4.1.2  Europe  (Germany,  UK,  France,  Italy,  Rest  of  Europe)
                4.1.3  Asia-Pacific  (China,  India,  Japan,  South  Korea,  Southeast  Asia,  Australia,  Rest  of  Asia  Pacific)
                4.1.4  South  America  (Brazil,,  Argentina,  Rest  of  Latin  America)
                4.1.5  Middle  East  and  Africa  (GCC,  North  Africa,  South  Africa,  Rest  of  Middle  East  and  Africa)
        4.2  Product  Type  Segmentation  (2017  to  2021f)
                4.2.1  Lubiprostone
                4.2.2  Linaclotide
                4.2.3  Eluxadoline
                4.2.4  Rifaximin
                4.2.5  Ramosetron  Hydrochloride
                4.2.6  Others
        4.3  Consumption  Segmentation  (2017  to  2021f)
                4.3.1  Hospital
                4.3.2  Clinic
                4.3.3  Home  Care
5    NORTH  AMERICA  MARKET  SEGMENT
        5.1  Region  Segmentation  (2017  to  2021f)
                5.1.1  U.S.
                5.1.2  Canada
                5.1.3  Mexico
        5.2  Product  Type  Segmentation  (2017  to  2021f)
                5.2.1  Lubiprostone
                5.2.2  Linaclotide
                5.2.3  Eluxadoline
                5.2.4  Rifaximin
                5.2.5  Ramosetron  Hydrochloride
                5.2.6  Others
        5.3  Consumption  Segmentation  (2017  to  2021f)
                5.3.1  Hospital
                5.3.2  Clinic
                5.3.3  Home  Care
        5.4  Impact  of  COVID-19  in  North  America
6    EUROPE  MARKET  SEGMENTATION
        6.1  Region  Segmentation  (2017  to  2021f)
                6.1.1  Germany
                6.1.2  UK
                6.1.3  France
                6.1.4  Italy
                6.1.5  Rest  of  Europe
        6.2  Product  Type  Segmentation  (2017  to  2021f)
                6.2.1  Lubiprostone
                6.2.2  Linaclotide
                6.2.3  Eluxadoline
                6.2.4  Rifaximin
                6.2.5  Ramosetron  Hydrochloride
                6.2.6  Others
        6.3  Consumption  Segmentation  (2017  to  2021f)
                6.3.1  Hospital
                6.3.2  Clinic
                6.3.3  Home  Care
        6.4    Impact  of  COVID-19  in  Europe
7    ASIA-PACIFIC  MARKET  SEGMENTATION
        7.1  Region  Segmentation  (2017  to  2021f)
                7.1.1  China
                7.1.2  India
                7.1.3  Japan
                7.1.4  South  Korea
                7.1.5  Southeast  Asia
                7.1.6  Australia
                7.1.7  Rest  of  Asia  Pacific
        7.2  Product  Type  Segmentation  (2017  to  2021f)
                7.2.1  Lubiprostone
                7.2.2  Linaclotide
                7.2.3  Eluxadoline
                7.2.4  Rifaximin
                7.2.5  Ramosetron  Hydrochloride
                7.2.6  Others
        7.3  Consumption  Segmentation  (2017  to  2021f)
                7.3.1  Hospital
                7.3.2  Clinic
                7.3.3  Home  Care
        7.4    Impact  of  COVID-19  in  Europe
8    SOUTH  AMERICA  MARKET  SEGMENTATION
        8.1  Region  Segmentation  (2017  to  2021f)
                8.1.1  Brazil
                8.1.2  Argentina
                8.1.3  Rest  of  Latin  America
        8.2  Product  Type  Segmentation  (2017  to  2021f)
                8.2.1  Lubiprostone
                8.2.2  Linaclotide
                8.2.3  Eluxadoline
                8.2.4  Rifaximin
                8.2.5  Ramosetron  Hydrochloride
                8.2.6  Others
        8.3  Consumption  Segmentation  (2017  to  2021f)
                8.3.1  Hospital
                8.3.2  Clinic
                8.3.3  Home  Care
        8.4    Impact  of  COVID-19  in  Europe
9    MIDDLE  EAST  AND  AFRICA  MARKET  SEGMENTATION
        9.1  Region  Segmentation  (2017  to  2021f)
                9.1.1  GCC
                9.1.2  North  Africa
                9.1.3  South  Africa
                9.1.4  Rest  of  Middle  East  and  Africa
        9.2  Product  Type  Segmentation  (2017  to  2021f)
                9.2.1  Lubiprostone
                9.2.2  Linaclotide
                9.2.3  Eluxadoline
                9.2.4  Rifaximin
                9.2.5  Ramosetron  Hydrochloride
                9.2.6  Others
        9.3  Consumption  Segmentation  (2017  to  2021f)
                9.3.1  Hospital
                9.3.2  Clinic
                9.3.3  Home  Care
        9.4    Impact  of  COVID-19  in  Europe
10  COMPETITION  OF  MAJOR  PLAYERS
        10.1  Brief  Introduction  of  Major  Players
                10.1.1  Abbott  Laboratories
                10.1.2  Synergy  Pharmaceuticals,  Inc.
                10.1.3  Sucampo  Pharmaceuticals,  Inc.
                10.1.4  Valeant  Pharmaceuticals  International,  Inc.
                10.1.5  Ardelyx,  Inc.
                10.1.6  Astellas  Pharma  Inc.
                10.1.7  Novartis  AG
                10.1.8  GlaxoSmithKline  plc.
                10.1.9  Ironwood  Pharmaceuticals,  Inc.
        10.2    Irritable  Bowel  Syndrome  Treatment  Sales  Date  of  Major  Players  (2017-2020e)
                10.2.1  Abbott  Laboratories
                10.2.2  Synergy  Pharmaceuticals,  Inc.
                10.2.3  Sucampo  Pharmaceuticals,  Inc.
                10.2.4  Valeant  Pharmaceuticals  International,  Inc.
                10.2.5  Ardelyx,  Inc.
                10.2.6  Astellas  Pharma  Inc.
                10.2.7  Novartis  AG
                10.2.8  GlaxoSmithKline  plc.
                10.2.9  Ironwood  Pharmaceuticals,  Inc.
        10.3    Market  Distribution  of  Major  Players
        10.4  Global  Competition  Segmentation
11    MARKET  FORECAST
        11.1    Forecast  by  Region
        11.2    Forecast  by  Demand
        11.3    Environment  Forecast
                11.3.1    Impact  of  COVID-19
                11.3.2    Geopolitics  Overview
                11.3.3    Economic  Overview  of  Major  Countries
12    REPORT  SUMMARY  STATEMENT
List of Table
1.Table Irritable Bowel Syndrome Treatment Product Type Overview
2.Table Irritable Bowel Syndrome Treatment Product Type Market Share List
3.Table Irritable Bowel Syndrome Treatment Product Type of Major Players
4.Table Brief Introduction of Abbott Laboratories
5.Table Brief Introduction of Synergy Pharmaceuticals, Inc.
6.Table Brief Introduction of Sucampo Pharmaceuticals, Inc.
7.Table Brief Introduction of Valeant Pharmaceuticals International, Inc.
8.Table Brief Introduction of Ardelyx, Inc.
9.Table Brief Introduction of Astellas Pharma Inc.
10.Table Brief Introduction of Novartis AG
11.Table Brief Introduction of GlaxoSmithKline plc.
12.Table Brief Introduction of Ironwood Pharmaceuticals, Inc.
13.Table Products & Services of Abbott Laboratories
14.Table Products & Services of Synergy Pharmaceuticals, Inc.
15.Table Products & Services of Sucampo Pharmaceuticals, Inc.
16.Table Products & Services of Valeant Pharmaceuticals International, Inc.
17.Table Products & Services of Ardelyx, Inc.
18.Table Products & Services of Astellas Pharma Inc.
19.Table Products & Services of Novartis AG
20.Table Products & Services of GlaxoSmithKline plc.
21.Table Products & Services of Ironwood Pharmaceuticals, Inc.
22.Table Market Distribution of Major Players
23.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
24.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
25.Table Global Irritable Bowel Syndrome Treatment Market Forecast (Million USD) by Region 2021f-2026f
26.Table Global Irritable Bowel Syndrome Treatment Market Forecast (Million USD) Share by Region 2021f-2026f
27.Table Global Irritable Bowel Syndrome Treatment Market Forecast (Million USD) by Demand 2021f-2026f
28.Table Global Irritable Bowel Syndrome Treatment Market Forecast (Million USD) Share by Demand 2021f-2026f




List of Figure
1.Figure Global Irritable Bowel Syndrome Treatment Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
2.Figure Global Irritable Bowel Syndrome Treatment Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
3.Figure Global Irritable Bowel Syndrome Treatment Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
4.Figure Global Irritable Bowel Syndrome Treatment Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
5.Figure Global Irritable Bowel Syndrome Treatment Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
6.Figure Global Irritable Bowel Syndrome Treatment Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
7.Figure Global Irritable Bowel Syndrome Treatment Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
8.Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
9.Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
10.Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
11.Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
12.Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
13.Figure Lubiprostone Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
14.Figure Linaclotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
15.Figure Eluxadoline Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
16.Figure Rifaximin Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
17.Figure Ramosetron Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
18.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
19.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
20.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
21.Figure Home Care Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
22.Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
23.Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
24.Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
25.Figure Lubiprostone Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
26.Figure Linaclotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
27.Figure Eluxadoline Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
28.Figure Rifaximin Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
29.Figure Ramosetron Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
30.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
31.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
32.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
33.Figure Home Care Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
34.Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
35.Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
36.Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
37.Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
38.Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
39.Figure Lubiprostone Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
40.Figure Linaclotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
41.Figure Eluxadoline Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
42.Figure Rifaximin Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
43.Figure Ramosetron Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
44.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
45.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
46.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
47.Figure Home Care Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
48.Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
49.Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
50.Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
51.Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
52.Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
53.Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
54.Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
55.Figure Lubiprostone Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
56.Figure Linaclotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
57.Figure Eluxadoline Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
58.Figure Rifaximin Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
59.Figure Ramosetron Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
60.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
61.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
62.Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
63.Figure Home Care Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
64.Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
65.Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
66.Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
67.Figure Lubiprostone Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
68.Figure Linaclotide Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
69.Figure Eluxadoline Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
70.Figure Rifaximin Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
71.Figure Ramosetron Hydrochloride Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
72.Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
73.Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
74.Figure Clinic Segmentation Market Size (USD Mil
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT